Incyte Shares Jump After ‘IDO’ Cancer Immunotherapy Combo Data Revealed – TheStreet.com
|
Incyte Shares Jump After 'IDO' Cancer Immunotherapy Combo Data Revealed
TheStreet.com Never-before-seen data from mid-stage clinical trials combining Incyte's (INCY) IDO inhibitor epacadostat with Keytruda and Opdivo, the anti-PD-1 checkpoint inhibitors marketed by Merck (MRK) and Bristol-Myers Squibb (BMY) , respectively, have been … |
